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A B S T R A C T
The Institute of Public Health for the Osijek-Baranja County (OBC) has processed the data on cancer patients that
were collected from mandatory county hospitals data reports, county bureaus of statistics and the County Register of
Deaths. The cancers were defined according to the International Statistical Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10), codes of malignant neoplasms of digestive organs (C15-C26). The aim of this article is
to show the size of the problem and the burden of the health care system caused by cancers of the digestive system (C15-
C26) in the OBC in the period 2001–2006. This article deals with cancer incidence and mortality data, appertaining age
distribution, cancer survival, median age at diagnosis and at death and length of stay in hospitals. The overall incidence
and mortality rate from cancer group C15-C26 (101.1 and 80/100,000, respectively, EU standard population) declined in
all age groups, comparing the data originating from the 2001-2003 period to the data referring to the 2004–2006 period.
The median age at diagnosis of cancer was 67.8 years with a shift of 0.91 year up in second period (the median age in the
first period was 67.3 years and in the second one 68.2 years). The median age at diagnosis of cancer in females was 69.7
years while in males was 66.3 years, which represents a difference of 2.9 years in favour of females. The overall relative
survival rate of all ages was 23.6%. This figure was slightly bigger for females (24.3%) than for males (23.1%). Concern-
ing all age groups, the number of hospital admissions of males increased during the observation period while the num-
ber of hospital admissions of women decreased at the same time. The average length of stay over the six years did not
changed significantly. Group of cancer C15-C26 was the most common group of cancers regarding both genders. The
five-year relative survival as one of the reliable benchmarks of the quality of the health care system needs to be raised to a
great extent in order to come nearer to the EU average within a short period of time.
Key words: cancer, digestive organs, ICD-10 codes C15-C26, colorectal cancer, stomach cancer, mortality rate, inci-
dence rate, 5-year relative survival, age at diagnosis, age at death, age distribution, median age, length of stay in hospi-
tal, Osijek-Baranja County
Introduction
Due to different lifestyles, different populations world-
wide experience different incidence rates of malignant
neoplasms of digestive organs (according to the Interna-
tional Statistical Classification of Diseases and Related
Health Problems, 10th Revision (ICD-10), codes C15–C26).
Colorectal cancer is one of the most common cancers in
this group (C18–C21). The incidence of colorectal cancer
has increased in most countries, except for the United
States and some areas of Japan. The most significant in-
creases have been observed in eastern European coun-
tries and most Asian countries1.
The incidence rates of cancer group C15–C26 vary a
lot worldwide with both genders. The highest rates con-
cern North America and Western Europe whereas the
lowest rates characterize Africa and South-Central Asia2.
Due to an increasing demand of cancer information on
cancer prevention, the Institute of Public Health of the
Osijek-Baranja County (IPHO) investigated this problem
in this article and tried to provide the precise informa-
tion on the cancer situation in the Osijek-Baranja Coun-
ty (OBC). On average, 4.3 people are diagnosed with
some type of cancer and 2.7 people die from cancer in the
OBC every day3. Among them, there were more males
(50.4% of all new cases of cancer and 58.9% of all cancer
deaths refer to males).
Both genders as a whole and males separately got
C15–C26 cancers more than any other cancer (the inci-
dence rate of 101 and 142/100,000, respectively) while
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this group of cancer was placed second among females
(the incidence rate of 73/100,000). In females, the first
place was reserved for breast cancer (C50) (79/100,000)3.
In the USA, as third most common cancer in both males
and females, colorectal cancer incidence rates have been
decreasing from 66.3/100,000 USA population in 1985 to
48.2/100,000 in 20044. In South Australia, the overall in-
cidence rate of group C15–C26 was 102.7/100.000 (world
population)5. In the EU and USA, colorectal cancer with
an annually estimated of 212,000 deaths a year accounts
for 12.3% of all deaths from cancer and is the second
most common cause of death from cancer. Stomach can-
cer occupies the fourth place (117,000 deaths, 6.8%)6,7.
The incidence rate in colorectal cancer is increasing rap-
idly, particularly in countries that have recently made
the transition from a relatively low-income economy to
high-income one8.
Five-year relative survival of colorectal cancer de-
pendent upon the stage of disease at diagnosis. In gen-
eral, the earlier the stage at diagnosis, the higher the
chance of survival9. It is estimated that the rate of gastric
cancer in the world in 2008 affected 8% of the total num-
ber of patients with cancer and accounts for 10% of all
deaths from cancer10. Stomachs cancer rates are two
times higher in males than in females. The highest inci-
dence rate in Europe is found in its eastern parts. Re-
gional variations in part reflect differences in dietary
patterns and the prevalence of Helicobacter pylori (H.
pylori) infection11. Increased use and availability of re-
frigeration, reductions in chronic H. pylori infection and
smoking in some parts of the world have decreased stom-
ach cancer rates12,13. In Croatia there was difference in
incidence rate of stomach cancer (C16) between conti-
nental and coastal area14.
A half of worldwide liver cancer cases and deaths are
estimated to occur in China, twice as often among men2.
This is a consequence of high prevalence of chronic hepa-
titis B and C virus infection. Interaction viruses and afla-
toxin B1 increased the possibility of liver cancer15. In the
USA and Central Europe, liver cancer incidence rates are
increasing due to the obesity and HCV infection (drug
users)16,17. On the contrary, universal infant and people
in risk vaccination for hepatitis B reduced liver cancer
incidence rates by about two-thirds in children and young
adults due to vaccination programs18.
The goal of this paper is to stress the complexity of
the issue and its influence on the health care system re-
garding cancers of digestive organs in the OBC in the pe-
riod from 2001 to 2006. General information on this can-
cer group has so far existed only on the national level and
only for particular sites.
Materials and Methods
Data source
Although the representativeness of their data might
be challenged, mandatory county hospitals data reports,
IPHO, county bureaus of statistics and the County Regis-
ter of Deaths still represent the only available source of
information on the profile of cancer in the OBC. All data
from the 2001–2006 period originate from these institu-
tions. Data obtained from the mandatory hospital re-
ports are accompanied with personal identification number
which represents a unique key for making connection
with other data obtained from various administrative
bodies in the OBC and their integration into a single da-
tabase. It was used the unique identification number of
each person that had the role of the key parameter of
linking data from different sources and different reports.
That way, every patient got their chronology of hospital-
ization.
The cohort studied in this article included all people
with cancer who were registered as the patients in one of
two hospitals in the OBC in the time period from 2001 to
2006 (follow up period from 1996 to 2010). Based on
these sources, a database of people who were hospitalized
in the area of the OBC for any reason whatsoever (in-
cluding cancer) has been generated19,20. The data on each
of the hospitalized patients have been supplemented
with data obtained from the Register of Deaths.
Data on every person with cancer are accompanied
with their chronological order of illness and hospitaliza-
tion. The database are involved all hospitalizations and
all data on ONKO or BSL forms (mandatory statistical
patterns for all hospitalized patients in Croatia). The
ONKO form is mandatory statistical reports on every
hospitalized cancer patients in Croatia. The BSL form is
a mandatory statistical report on every hospitalized per-
son, regardless of the causes of hospitalization. All can-
cer patients are hospitalized in the state-owned (public)
hospitals since there are still the only hospitals here.
Statistical analysis
The cancer group of malignant neoplasms of digestive
organs, codes C15–C26, was classified according to the
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision, Version for
2010 (ICD-10). The cancer incidence and mortality esti-
mates in the period from 2001 to 2006 were prepared for
all cancers based on gender and for age groups 0–19,
20–44, 45–64, 65+ by the year at diagnosis of cancer.
Based on the 2001 census, the analysis covered a total
population of 330.506 people in OBC. The Croatian Na-
tional Health Insurance is a universal health insurance
that covers all or almost all the costs (depends on per-
sonal participation) of treatment of Croatian citizens and
provides them with the same chances of recovery. There-
fore, in this article we write about the entire population
of cancer patients treated in the OBC.
Descriptive statistics were used for age and gender.
The survival rates denote the outcome up to 5 years after
diagnosis for cancer patients who were diagnosed during
the 2001–2005 period. All survival estimates were age-
-adjusted, on the basis of four age groups: 0–19, 20–44,
45–64, 65+ years. The analyses were conducted using
age-specific rates, the age-standardization-direct method
and 95% confidence intervals (95% CI). The standardized
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incidence and mortality ratios as well as the 95% confi-
dence intervals were computed for C15–C26 pursuant to
the year at diagnosis of cancer. Also, both ratios were
stratified by year at diagnosis of cancer, age and gender
and adjusted for 3-years time periods 2001–2003, 2004–
2006. The median age was the observation ranked in the
middle; that is 50% of patients are diagnosed at an older
age and 50% are diagnosed at a younger age compared to
the median. The EU standard population was used in the
analysis21. Length of stay was determined according to
the date of admission and to the date of discharge with
regard to the index admission. The SAS statistical pack-
age (version 9.1, SAS Institute INC., Cary, NC, SAD) was
used for statistical analysis22 and Microsoft® Office Ex-
cel® 2007.
Results
According to the 2001 census, the analysis covered a
total population of 330,506 people in the OBC. From
2001 to 2006, a total of 2,444 people were registered with
cancer C15–C26 and treated at the two hospitals in the
OBC. The observed period was divided into two three-
-year periods, the first one comprises the 2001–2003 pe-
riod and the second one the 2004–2006. The percentage
of females among all patients who were diagnosed with
cancer numbers 43.7% (1,068) while this percentage for
males was 56.3% (1,376). The mean incidence of new
C15–C26 cancers over the 6-year study period (2001–
2006) amounted to 407 cases/year, equating to the OBC
population age-adjusted incidence rate of 101.1/100,000
(Table 1).
The incidence rate observed in the two periods signifi-
cantly decreased in females in second period (from 77.3
to 69.1/100,000, Figure 2, R2=0.822) and for males (from
144.7 to 138.5/100,000) (Table 1). The overall incidence
rate of cancer in males was twice as high as the rate for
females (141.6/100,000 and 73.2/100,000).
In the OBC 328 patients died of cancer group C15–C26
on a yearly basis on average, which implies the mortality
rate of 80/100,000 (Table 1, Figure 2). Regarding both
gender, the mortality rate fell from 83.4/100,000 in first
period to 76.6/100,000 in second period. The mortality
rate in females and males equally fall in both periods (fe-
males – from 60 to 53.7/100,000, males – from 117.8 to
110.2/100,000). Like the incidence rate, the death ratio
in male and female was almost twice as high in favour of
male.
In 2001–2006 period, the median age at diagnosis for
C15–C26 cancer was 67.8 years, precisely 66.3 for males
and 69.7 for females with median age difference of 3.4
years between genders (Table 2, Figure 1). As far as both
genders are concerned, the cancers were on average diag-
nosed 0.91 years later in the second period. Regarding
the oldest age group, the most common cancers were can-
cer of other and ill-defined digestive organs (C26) and
cancer of gallbladder (C23) (72.8 and 72.6 years, respec-
tively) whereas the youngest population was often diag-
nosed with oesophagus cancer (C15) and small intestine
cancer (C17) (63 and 64.9 years, respectively). The me-
dian age at death from C15–C26 cancers was 70.2 years,
68.5 years for males and 72.5 years for females, which en-
tails the difference of 4 years between the genders.
The total incidence rate for the entire cancer group
was 101.1/100,000 (SD±5.1, CI 91.2–111, Table 3, Figure
2). With respect to all cancer group, females tend to be
two times (52% of male cases) less diagnosed to cancer
than males (73.2/100,000, SD±5.7, CI 62.2–84.3 and
141.6/100,000, SD±9.3, CI 123.3–159.9, respectively).
Pertaining to both genders, colon cancer (C18) and stom-
ach cancer (C16) were the cancer sites with the highest
incidence rate. Colorectal cancer (C18–C21) made up al-
most half of all cancer patients in the C15–C26 group
(48/100,000). Colon cancer (C18), gastric cancer (C16)
and cancer of rectum (C20) made up 2/3 of all patients
(24.2, 21.5 and 19.1/100,000, respectively). The age-stan-
dardize incidence rate for colon cancer (C18) as the most
frequent malignant tumour in both genders increased
from 23.2/100,000 in the first period to 25.3/100,000 in
the second one. The incidence rate of the next two most
frequent cancers, stomach cancer (C16) and rectum can-
cer (C20) decreased sharply in the second period (C16,
from 25.1 to 17.9/100,000 and C20, from 21.9 to 16.3/
100,000, respectively). In females, C18 was the cancer
site with the highest incidence rate. It is followed by can-
cer sites C20 and C16 (18.9, 14.3 and 14.3/100,000, re-
spectively). In males, the highest incidence rate refers to
C16 cancer site with incidence rate of 33.8/100,000. Can-
cer occurs primarily at ages 65+, and was four times
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TABLE 1
HISTORICAL DATA ON C15–C26 CANCER AGE-STANDARDIZED INCIDENCE AND MORTALITY NUMBER AND RATE PER 100,000
(USING EU STANDARD POPULATION) COVERED THE PERIOD FROM 2001–2006
Year of data
collection
Incidence rate Mortality rate
Males Females Both genders Males Females Both genders
N ASR N ASR N ASR N ASR N ASR N ASR
2001–2003 234 144.7 188 77.3 422 104.9 191 117.8 150 60.0 341 83.4
2004–2005 224 138.5 168 69.1 393 97.2 179 110.2 135 53.7 314 76.6
2001–2006 229 141.6 178 73.2 407 101.1 185 114.0 143 56.8 328 80.0
N – average number of cases per year, ASR – age-standardized rate (EU)
more frequent in that age category than in all younger
age groups.
The incidence rate of colorectal cancer decrease from
49.8 to 46.3/100,000 and it was particularly obvious in
the 60+ age group (from 270 to 257.2/100,000). In the
45–64 and 65+ age groups, males were two times more
inclined to C15–C26 cancers than women whereas in
younger age groups, there was no difference between the
genders. In both observation periods, a significantly low-
er mortality rate was determined for all C15–C26 cancer
group (from 83.4 to 76.6/100,000) in both gender (Table
4, Figure 3). In the end, a significant decrease in female-
-to-female incidence and mortality rate ratio (Tables 3
and 4) was observed with the C20 and C16 cancer sites in
the 65+ age group in the second period.
The relative 5-year survival rate varies with age and
cancer site (Table 5, Figure 4). Patients in the OBC diag-
nosed with the cancer group C15–C26 were character-
ized by the overall age-adjusted 5-year relative survival
rate of 23.6%. The average survival rate in males amo-
unted to 23.1% and in females to 24.3%.
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TABLE 2
THE MEDIAN AGE AT DIAGNOSIS AND AT DEATH FOR C15–C26 CANCER IN OBC, PERIODS 2001–2003 AND 2004–2006, BOTH GENDER













































































Median age (in years) at diagnosis
C15 67.4 (18) 70.3 (7) 65.5 (11) –4.84 62.2 (102) 61.9 (51) 62.6 (51) 0.77 63.0 (120) 62.9 (58) 63.1 (62) 0.26
C16 68.9 (195) 67.8 (124) 70.8 (71) 3.00 67.7 (329) 66.3 (179) 69.4 (150) 3.19 68.2 (524) 66.9 (303) 69.9 (221) 2.99
C17 69.9 (8) 68.3 (4) 71.4 (4) 3.13 58.3 (6) 50.5 (3) 66.2 (3) 15.65 64.9 (14) 60.7 (7) 69.2 (7) 8.49
C18 69.2 (274) 69.1 (127) 69.3 (147) 0.27 66.3 (312) 66.2 (153) 66.3 (159) 0.10 67.6 (586) 67.5 (280) 67.8 (306) 0.26
C19 68.6 (47) 67.7 (25) 69.6 (22) 1.86 67.4 (61) 67.0 (28) 67.7 (33) 0.70 67.9 (108) 67.3 (53) 68.4 (55) 1.11
C20 68.3 (202) 68.5 (121) 67.9 (81) –0.64 65.8 (255) 65.5 (141) 66.3 (114) 0.83 66.9 (457) 66.9 (262) 67 (195) 0.08
C21 70.6 (6) 69.8 (3) 71.5 (3) 1.69 61.8 (1) 61.8 (1) – – 69.4 (7) 67.8 (4) 71.5 (3) 3.67
C22 71.0 (97) 70.9 (52) 71.2 (45) 0.36 67.1 (123) 67.3 (65) 66.9 (58) –0.46 68.8 (220) 68.9 (117) 68.8 (103) –0.13
C23 74.2 (59) 73.1 (27) 75.2 (32) 2.10 68.4 (23) 68.4 (8) 68.4 (15) 0.03 72.6 (82) 72.0 (35) 73.0 (47) 1.02
C24 71.9 (20) 66.6 (2) 72.5 (18) 5.91 71.3 (17) 69.4 (7) 72.5 (10) 3.14 71.6 (37) 68.8 (9) 72.5 (28) 3.75
C25 70.4 (120) 70.3 (57) 70.5 (63) 0.18 64.8 (136) 65.6 (64) 64.1 (72) –1.58 67.4 (256) 67.9 (121) 67.1 (135) –0.78
C26 74.9 (22) 74.6 (14) 75.4 (8) 0.71 68.7 (11) 61.4 (3) 71.5 (8) 10.04 72.8 (33) 72.3 (17) 73.4 (16) 1.11
C18–C21 68.8 (529) 68.7 (276) 68.9 (253) 0.20 66.2 (629) 65.9 (323) 66.5 (306) 0.51 67.4 (1158) 67.2 (599) 67.6 (559) 0.35
C23–C24 73.6 (79) 72.6 (29) 74.2 (50) 1.60 69.6 (40) 68.8 (15) 70.1 (25) 1.20 72.3 (119) 71.3 (44) 72.8 (75) 1.49
C15–C26 69.7 (1,068) 69.2 (563) 70.2 (505) 0.91 66.3 (1,376) 65.8 (703) 66.8 (673) 1.00 67.8 (2,444) 67.3 (1,266) 68.2 (1,178) 0.91
Median age (in years) at death
C15 71.4 (15) 70.8 (7) 71.9 (8) 1.18 63.1 (94) 63.1 (46) 63.1 (48) –0.07 64.2 (109) 64.1 (53) 64.3 (56) 0.19
C16 71.5 (167) 70.4 (108) 73.4 (59) 2.92 69.1 (303) 68.1 (165) 70.2 (138) 2.12 69.9 (470) 69.0 (273) 71.2 (197) 2.14
C17 69.9 (6) 66.7 (3) 73.2 (3) 6.54 60.6 (4) 47.8 (2) 73.5 (2) 25.75 66.2 (10) 59.1 (5) 73.3 (5) 14.22
C18 72.9 (191) 72.8 (90) 73.0 (101) 0.14 69.9 (207) 69.9 (107) 70.0 (100) 0.07 71.3 (398) 71.2 (197) 71.5 (201) 0.24
C19 74.9 (27) 73.8 (13) 75.8 (14) 2.03 70.1 (33) 67.3 (14) 72.2 (19) 4.91 72.3 (60) 70.4 (27) 73.8 (33) 3.32
C20 72.4 (142) 73.5 (84) 70.7 (58) –2.79 69.7 (183) 69.3 (105) 70.3 (78) 1.00 70.9 (325) 71.2 (189) 70.5 (136) –0.70
C21 71.4 (6) 70.2 (3) 72.6 (3) 2.47 – – – – 71.4 (6) 70.2 (3) 72.6 (3) 2.47
C22 71.9 (93) 72.1 (48) 71.8 (45) –0.24 68 (115) 68.7 (61) 67.1 (54) –1.59 69.8 (208) 70.2 (109) 69.3 (99) –0.93
C23 74.5 (59) 73.4 (27) 75.5 (32) 2.10 69.3 (22) 70.2 (7) 68.8 (15) –1.43 73.1 (81) 72.7 (34) 73.3 (47) 0.62
C24 75.9 (17) 66.7 (2) 77.1 (15) 10.41 72.3 (16) 70.1 (7) 74.0 (9) 3.91 74.1 (33) 69.3 (9) 76.0 (24) 6.63
C25 71.2 (115) 71.4 (54) 71.1 (61) –0.35 66.3 (122) 68.4 (56) 64.6 (66) –3.80 68.7 (237) 69.9 (110) 67.7 (127) –2.17
C26 78.2 (18) 78.2 (12) 78.2 (6) –0.03 69.5 (10) 62.0 (3) 72.8 (7) 10.80 75.1 (28) 75.0 (15) 75.3 (13) 0.30
C18-C21 72.8 (366) 73.2 (190) 72.4 (176) –0.71 69.8 (423) 69.4 (226) 70.3 (197) 0.86 71.2 (789) 71.1 (416) 71.3 (373) 0.18
C23-C24 74.8 (76) 72.9 (29) 76.0 (47) 3.09 70.5 (38) 70.1 (14) 70.7 (24) 0.59 73.4 (114) 72.0 (43) 74.2 (71) 2.21
C15-C26 72.5 (856) 72.2 (451) 72.8 (405) 0.58 68.5 (1,109) 68.3 (573) 68.7 (536) 0.40 70.2 (1,965) 70 (1,024) 70.4 (941) 0.44
Difference (in years) = period II (2004–2006) – period I (2001–2003)
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Fig. 1. The median age (in years) of cancer patients at diagnosis (MADg) and at death (MAD) by primary cancer site (C15–C26 in the
OBC, periods 2001–2006. The rising trendlines in females suggests that a very strong and extremely dependable relationship exist
between the median age at diagnosis and years, R2=0.849 (R2>0.80) and strong relationship in males, R2=0.721 (R2>0.48<0.81).
The lowest survival rates were found with gallbladder
cancer (C23) and cancer of liver and intrahepatic bile
ducts (C22) (3.3% and 7.7%, respectively). No females
survived cancer site C23 for five years or more. In the en-
tire cancer group, the difference in 5-year relative sur-
vival rate between males and females was 1.2 percentage
points in favour of females. Males with cancer of pan-
creas (C25) had the survival rate of 12.7%, while females’
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Fig. 1. continued.
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Fig. 2. The cancer age-standardized incidence rate (ASIR) for cancer group C15–C26 in the period 2001–2006 in the OBC per 100,000
inhabitants using the EU standard population. The downward trendline in females suggest that a very strong and extremely depend-
able relationship exists between ASIR and years, R2=0.822 (R2>0.80) and moderate downward trendline relationship in males
(R2=0.365, (R2>0.16<0.49)).
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TABLE 3
THE AGE-STANDARDIZED INCIDENCE RATE OF C15–C26 CANCERS IN THE OBC PER 100,000 IN THE TWO PERIODS




0–19 20–44 45–64 65+ All ages
I II T I II T I II T I II T I II T
C15 – – – – – – 1.6 3.9 2.7 5.3 6.4 5.8 1.0 1.7 1.3
C16 0.8 – 0.4 4.6 1.7 3.2 19.6 10.9 15.2 95.4 57.2 76.3 17.2 9.6 13.4
C17 – – – 0.6 – 0.3 – – – 3.2 4.2 3.7 0.6 0.5 0.5
C18 – – – 1.7 2.9 2.3 25.8 25.8 25.8 96.4 115.5 106.0 17.7 20.2 18.9
C19 – – – 0.6 0.6 0.6 4.7 2.3 3.5 19.1 19.1 19.1 3.5 2.9 3.2
C20 – – – 2.9 1.7 2.3 24.2 18.8 21.5 90.1 57.2 73.6 17.0 11.6 14.3
C21 – – – – – – 0.8 0.8 0.8 2.1 2.1 2.1 0.4 0.4 0.4
C22 – – – 0.6 – 0.3 7.0 9.4 8.2 44.5 35.0 39.7 6.9 6.2 6.5
C23 – – – – – – 5.5 1.6 3.5 21.2 31.8 26.5 3.7 3.9 3.8
C24 – – – – – – – 1.6 0.8 2.1 17.0 9.5 0.2 2.3 1.2
C25 – – – 0.6 0.6 0.6 7.8 14.1 10.9 48.7 46.6 47.7 7.5 8.9 8.2
C26 – – – – – – 0.8 1.6 1.2 13.8 6.4 10.1 1.7 1.1 1.4
C18–C21 – – – 5.2 5.2 5.2 55.5 47.7 51.6 207.7 193.9 200.8 38.6 35.1 36.8
C23–C24 – – – – – – 5.5 3.1 4.3 23.3 48.7 36.0 3.9 6.1 5.0
C15–C26 0.8 – 0.4 11.6 7.5 9.6 97.8 90.7 94.2 441.9 398.4 420.1 77.3 69.1 73.2
Males
ICD-10
0–19 20–44 45–64 65+ All ages
I II T I II T I II T I II T I II T
C15 – – – – – – 23.4 23.4 23.4 42.8 40.9 41.8 10.5 10.6 10.6
C16 – – – 2.9 1.1 2.0 49.2 49.2 49.2 213.9 208.3 211.1 36.8 30.8 33.8
C17 – – – 0.6 – 0.3 1.7 1.7 1.7 – 3.7 1.9 0.6 0.6 0.6
C18 – – – 2.3 3.4 2.9 42.6 42.6 42.6 182.3 189.7 186.0 31.5 32.7 32.1
C19 – 0.8 0.4 0.6 – 0.3 5.8 5.8 5.8 37.2 46.5 41.8 5.8 6.8 6.3
C20 – – – 4.6 2.3 3.4 39.2 39.2 39.2 159.9 132.0 146.0 29.0 23.5 26.2
C21 – – – – – – 0.8 0.8 0.8 – – – 0.2 – 0.1
C22 – – – 0.6 2.3 1.4 16.7 16.7 16.7 81.8 68.8 75.3 13.4 11.9 12.6
C23 – – – – – – 2.5 2.5 2.5 9.3 20.5 14.9 1.6 3.1 2.4
C24 – – – – – – 1.7 1.7 1.7 9.3 13.0 11.2 1.4 2.1 1.7
C25 – – – 1.1 1.7 1.4 16.7 16.7 16.7 78.1 78.1 78.1 13.2 14.8 14.0
C26 – – – 0.6 – 0.3 – – – 3.7 13.0 8.4 0.6 1.6 1.1
C18–C21 – 0.8 0.4 7.4 5.7 6.6 88.5 88.5 88.5 379.4 368.2 373.8 66.4 63.0 64.7
C23–C24 – – – – – – 4.2 4.2 4.2 18.6 33.5 26.0 3.1 5.1 4.1
C15–C26 – 0.8 0.4 13.1 10.8 12.0 200.3 200.3 200.3 818.3 814.6 816.5 144.7 138.5 141.6
Both genders
ICD-10
0–19 20–44 45–64 65+ All ages
I II T I II T I II T I II T I II T
C15 – – – – – – 12.1 12.1 12.1 18.9 18.9 18.9 5.1 5.5 5.3
C16 0.4 – 0.2 3.7 1.4 2.6 33.9 33.9 33.9 138.4 112.1 125.2 25.1 17.9 21.5
C17 – – – 0.6 – 0.3 0.8 0.8 0.8 2.0 4.1 3.0 0.6 0.5 0.6
C18 – – – 2.0 3.2 2.6 33.9 33.9 33.9 127.6 142.4 135.0 23.2 25.3 24.2
C19 – 0.4 0.2 0.6 0.3 0.4 5.2 5.2 5.2 25.7 29.0 27.3 4.3 4.4 4.4
C20 – – – 3.7 2.0 2.9 31.5 31.5 31.5 115.4 84.4 99.9 21.9 16.3 19.1
C21 – – – – – – 0.8 0.8 0.8 1.4 1.4 1.4 0.4 0.2 0.3
C22 – – – 0.6 1.1 0.9 11.7 11.7 11.7 58.1 47.3 52.7 9.5 8.5 9.0
C23 – – – – – – 4.0 4.0 4.0 16.9 27.7 22.3 2.9 3.6 3.3
C24 – – – – – – 0.8 0.8 0.8 4.7 15.5 10.1 0.7 2.2 1.5
C25 – – – 0.9 1.1 1.0 12.1 12.1 12.1 59.4 58.1 58.7 9.9 11.3 10.6
C26 – – – 0.3 – 0.1 0.4 0.4 0.4 10.1 8.8 9.5 1.3 1.3 1.3
C18–C21 – 0.4 0.2 6.3 5.5 5.9 71.5 71.5 71.5 270.0 257.2 263.6 49.8 46.3 48.0
C23–C24 – – – – – – 4.8 4.8 4.8 21.6 43.2 32.4 3.6 5.9 4.7
C15–C26 0.4 0.4 0.4 12.4 9.2 10.8 147.4 147.4 147.4 578.5 549.5 564.0 104.9 97.2 101.1
Years of data collection: I – 2001–2003, II – 2004–2006, T – 2001–2006
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TABLE 4
AGE-STANDARDIZED MORTALITY RATES FOR C15–C26 CANCERS IN TWO PERIODS (BY AGE GROUP AND GENDER) IN OBC PER




20–44 45–64 65+ All ages
I II T I II T I II T I II T
C15 – – – 1.6 1.6 1.6 5.3 6.4 5.8 1.0 1.1 1.0
C16 2.3 0.6 1.4 18.0 8.6 13.3 85.8 49.8 67.8 14.7 7.8 11.3
C17 0.6 – 0.3 – – – 2.1 3.2 2.6 0.4 0.3 0.4
C18 – 1.2 0.6 16.4 10.9 13.7 73.1 90.1 81.6 12.1 13.0 12.6
C19 – – – 0.8 0.8 0.8 12.7 13.8 13.2 1.6 1.7 1.7
C20 0.6 1.2 0.9 10.9 11.7 11.3 73.1 43.4 58.3 11.0 8.1 9.5
C21 – – – 0.8 0.8 0.8 2.1 2.1 2.1 0.4 0.4 0.4
C22 0.6 – 0.3 6.3 9.4 7.8 41.3 35.0 38.1 6.3 6.2 6.3
C23 – – – 5.5 1.6 3.5 21.2 31.8 26.5 3.7 3.9 3.8
C24 – – – – – – 2.1 15.9 9.0 0.2 1.7 1.0
C25 0.6 – 0.3 6.3 14.1 10.2 47.7 45.6 46.6 7.0 8.5 7.8
C26 – – – – 0.8 0.4 12.7 5.3 9.0 1.4 0.8 1.1
C18–C21 0.6 2.3 1.4 28.9 24.2 26.6 161.1 149.4 155.2 25.2 23.3 24.2
C23–C24 – – – 5.5 1.6 3.5 23.3 47.7 35.5 3.9 5.6 4.8
C15–C26 4.6 2.9 3.8 66.5 60.2 63.3 379.3 342.3 360.8 60.0 53.7 56.8
Males
ICD-10
20–44 45–64 65+ All ages
I II T I II T I II T I II T
C15 – – – 19.2 19.2 19.2 42.8 37.2 40.0 9.5 9.9 9.7
C16 2.9 1.1 2.0 39.2 39.2 39.2 210.2 189.7 199.9 33.9 28.4 31.1
C17 0.6 – 0.3 0.8 0.8 0.8 – 3.7 1.9 0.4 0.4 0.4
C18 0.6 1.1 0.9 23.4 23.4 23.4 145.1 137.6 141.3 22.0 20.5 21.3
C19 0.6 – 0.3 3.3 3.3 3.3 16.7 31.6 24.2 2.9 3.9 3.4
C20 1.7 1.7 1.7 26.7 26.7 26.7 130.2 104.1 117.2 21.6 16.0 18.8
C21 – – – – – – – – – – – –
C22 0.6 1.7 1.1 13.4 13.4 13.4 81.8 63.2 72.5 12.5 11.1 11.8
C23 – – – 1.7 1.7 1.7 9.3 20.5 14.9 1.4 3.1 2.3
C24 – – – 1.7 1.7 1.7 9.3 11.2 10.2 1.4 1.9 1.6
C25 1.1 1.7 1.4 10.0 10.0 10.0 78.1 70.7 74.4 11.5 13.6 12.5
C26 0.6 – 0.3 – – – 3.7 11.2 7.4 0.6 1.4 1.0
C18–C21 2.9 2.9 2.9 53.4 53.4 53.4 292.0 273.4 282.7 46.5 40.5 43.5
C23–C24 – – – 3.3 3.3 3.3 18.6 31.6 25.1 2.9 4.9 3.9
C15–C26 8.6 7.4 8.0 139.4 139.4 139.4 727.2 680.7 703.9 117.8 110.2 114.0
Both genders
ICD-10
20–44 45–64 65+ All ages
I II T I II T I II T I II T
C15 – – – 10.1 10.1 10.1 18.9 17.6 18.2 4.6 5.0 4.8
C16 2.6 0.9 1.7 28.3 28.3 28.3 131.0 100.6 115.8 22.4 15.9 19.1
C17 0.6 – 0.3 0.4 0.4 0.4 1.4 3.4 2.4 0.5 0.4 0.4
C18 0.3 1.1 0.7 19.8 19.8 19.8 99.2 107.3 103.3 16.0 16.0 16.0
C19 0.3 – 0.1 2.0 2.0 2.0 14.2 20.3 17.2 2.2 2.5 2.3
C20 1.1 1.4 1.3 18.6 18.6 18.6 93.8 65.5 79.7 15.4 11.1 13.3
C21 – – – 0.4 0.4 0.4 1.4 1.4 1.4 0.2 0.2 0.2
C22 0.6 0.9 0.7 9.7 9.7 9.7 56.0 45.2 50.6 8.8 8.2 8.5
C23 – – – 3.6 3.6 3.6 16.9 27.7 22.3 2.8 3.6 3.2
C24 – – – 0.8 0.8 0.8 4.7 14.2 9.5 0.7 1.9 1.3
C25 0.9 0.9 0.9 8.1 8.1 8.1 58.7 54.7 56.7 8.8 10.7 9.7
C26 0.3 – 0.1 – – – 9.5 7.4 8.4 1.1 1.0 1.1
C18–C21 1.7 2.6 2.2 40.8 40.8 40.8 208.6 194.4 201.5 33.7 30.0 31.9
C23–C24 – – – 4.4 4.4 4.4 21.6 41.9 31.7 3.5 5.5 4.5
C15–C26 6.6 5.2 5.9 101.7 101.7 101.7 505.6 465.1 485.3 83.4 76.6 80.0
Years of data collection: I – 2001–2003, II – 2004–2006, T – 2001–2006, Age 0–19 – no death
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TABLE 5
OVERALL FIVE YEARS RELATIVE SURVIVAL RATES FOR C15–C26 CANCERS IN THE OBC, BOTH GENDERS, PERIOD 2001–2005
ICD-10
Females – % (number of survival cases)
0–19 20–44 45–64 65+ All ages
C15 – – 50.5 (3) 0.0 19.0 (3)
C16 100.1 (1) 58.4 (7) 21.3 (8) 15.9 (18) 20.0 (34)
C17 – 0.0 – 64.0 (3) 50.6 (3)
C18 – 66.7 (4) 47.9 (27) 29.6 (43) 34.4 (74)
C19 – 100.1 (2) 80.8 (8) 34.3 (9) 48.1 (19)
C20 – 66.7 (6) 54.7 (26) 27.5 (32) 35.8 (64)
C21 – – 0.0 0.0 0.0
C22 – 0.0 18.4 (4) 5.2 (3) 8.3 (7)
C23 – – 0.0 0.0 0.0
C24 – – 101 (1) 8.9 (1) 15.6 (2)
C25 – 50.1 (1) 9.6 (2) 2.9 (2) 5.3 (5)
C26 – – 50.5 (1) 15.2 (2) 19.0 (3)
C18–C21 – 70.7 (12) 52.7 (61) 28.9 (84) 35.8 (157)
C23–C24 – – 11.2 (1) 2.2 (1) 3.6 (2)
C15–C26 100.1 (1) 60.7 (20) 37.6 (80) 18.7 (113) 24.3 (214)
ICD-10
Males – % (number of survival cases)
0–19 20–44 45–64 65+ All ages
C15 – 0.0 13.3 (7) 0.0 8.3 (7)
C16 – 16.7 (1) 25.8 (23) 7.9 (14) 13.5 (38)
C17 – 0.0 50.5 (1) 0.0 20.3 (1)
C18 – 75.1 (6) 51.6 (47) 27.8 (43) 36.7 (96)
C19 100.1 (1) 0.0 57.7 (8) 53.3 (16) 52.8 (25)
C20 – 54.6 (6) 47.1 (41) 22.8 (25) 33.8 (72)
C21 – – 101.0 (1) – 101.3 (1)
C22 – 20.0 (1) 16.8 (5) 1.7 (1) 7.2 (7)
C23 – – 20.2 (1) 8.2 (1) 11.3 (2)
C24 – – 16.8 (1) 0.0 7.2 (1)
C25 – 20.0 (1) 27.8 (11) 1.6 (1) 11.9 (13)
C26 – 0.0 – 15.2 (1) 12.7 (1)
C18–C21 100.1 (1) 60.1 (12) 50.3 (97) 28.5 (84) 37.1 (194)
C23–C24 – – 18.4 (2) 5.1 (1) 9.5 (3)
C15–C26 100.1 (1) 38.5 (15) 35.0 (146) 15.6 (102) 23.1 (264)
ICD-10
Both genders – % (number of survival cases)
0–19 20–44 45–64 65+ All ages
C15 – 0.0 17.1 (10) 0.0 10.0 (10)
C16 100.1 (1) 44.5 (8) 24.5 (31) 11.0 (32) 15.9 (72)
C17 – 0.0 50.5 (1) 45.7 (3) 36.8 (4)
C18 – 71.5 (10) 50.2 (74) 28.6 (86) 35.6 (170)
C19 100.1 (1) 66.7 (2) 67.4 (16) 44.4 (25) 50.6 (44)
C20 – 60.1 (12) 49.8 (67) 25.2 (57) 34.7 (136)
C21 – – 33.7 (1) 0.0 16.9 (1)
C22 – 16.7 (1) 17.5 (9) 3.4 (4) 7.7 (14)
C23 – – 7.8 (1) 2.2 (1) 3.3 (2)
C24 – – 28.9 (2) 5.3 (1) 11.3 (3)
C25 – 28.6 (2) 21.5 (13) 2.3 (3) 8.8 (18)
C26 – 0.0 50.5 (1) 15.2 (3) 16.9 (4)
C18–C21 100.1 (1) 64.9 (24) 51.2 (158) 28.7 (168) 36.5 (351)
C23–C24 – – 15.2 (3) 3.1 (2) 5.7 (5)
C15–C26 100.1 (2) 48.7 (35) 35.9 (226) 17.1 (215) 23.6 (478)
– “–” – no cases, 0.0 – no survival cases
survival rate was twice as low, only 5.3%. Comprising
both genders, cancer group C15–C26 was featured by the
range of survival rates from 3.3% to 50.6%.
Over the 6-year study period, the number of C15–C26
cases decreased (Table 1 and 2). The age distribution at
diagnosis and at death for each age group is showed in
the Table 6. The proportion of females under 45 years of
age in this cancer group was slightly higher (3.6%) than
that of males (3.4%). Vice versa, the mortality rate in the
same cancer group was almost twice higher in males
(2.9%) than in females (1.6%). One can say that cancer
group C15–C26 is the cancer of the 65+ age group. At
that age, females developed cancer and died of it (72.8%
and 78.4%, respectively) more often than males (60.6%
and 65.7%, respectively).
In the 2001–2006 period, a total of 2,444 people were
diagnosed with C15–C26 cancers. In this period, the hos-
pital admissions in the OBC hospitals counted 4,642 and
the total days of hospital care numbered 73,671. On aver-
age, one patient was hospitalized 1.9 times during this
reference period with the average length of stay of 15.9
days (Table 7, Figure 5). The number of hospitalizations
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TABLE 6
THE AGE DISTRIBUTION OF CANCER PACIENTS AT DIAGNOSIS AND AT DEATH FOR C15–C26 CANCERS IN PERIOD 2001–2006,
BOTH GENDERS
ICD-10
Age distribution (%) at diagnosis Frequency
(number of cases)
Frequency
(%)Females Males Both genders
0–44 45–64 65+ 0–44 45–64 65+ 0–44 45–64 65+ F M T F M T
C15 – 38.9 61.1 2.0 59.8 38.2 1.7 56.7 41.7 18 102 120 1.7 7.4 4.9
C16 6.7 21.5 71.8 2.1 31.6 66.3 3.8 27.9 68.3 195 329 524 18.3 23.9 21.4
C17 12.5 – 87.5 16.7 50.0 33.3 14.3 21.4 64.3 8 6 14 0.7 0.4 0.6
C18 2.9 25.2 71.9 3.2 35.6 61.2 3.1 30.7 66.2 274 312 586 25.7 22.7 24.0
C19 4.3 25.5 70.2 1.6 24.6 72.1 2.8 25.0 71.3 47 61 108 4.4 4.4 4.4
C20 5.0 27.2 67.8 4.7 38.0 57.3 4.8 33.3 61.9 202 255 457 18.9 18.5 18.7
C21 – 33.3 66.7 – 100.0 – – 42.9 57.1 6 1 7 0.6 0.1 0.3
C22 1.0 25.8 73.2 5.7 30.9 63.4 3.6 28.6 67.7 97 123 220 9.1 8.9 9.0
C23 – 15.3 84.7 – 34.8 65.2 – 20.7 79.3 59 23 82 5.5 1.7 3.4
C24 5.0 5.0 90.0 – 35.3 64.7 2.7 18.9 78.4 20 17 37 1.9 1.2 1.5
C25 1.7 23.3 75.0 4.4 36.0 59.6 3.1 30.1 66.8 120 136 256 11.2 9.9 10.5
C26 – 13.6 86.4 9.1 9.1 81.8 3.0 12.1 84.8 22 11 33 2.1 0.8 1.4
C18–C21 3.8 26.1 70.1 3.7 35.6 60.6 3.7 31.3 64.9 529 629 1158 49.5 45.7 47.4
C23–C24 1.3 12.7 86.1 – 35.0 65.0 0.8 20.2 79.0 79 40 119 7.4 2.9 4.9
C15–C26 3.6 23.7 72.8 3.4 35.9 60.6 3.5 30.6 65.9 1,068 1,376 2,444 43.7 56.3
ICD-10
Age distribution (%) at deaths Frequency
(number of cases)
Frequency
(%)Females Males Both genders
0–44 45–64 65+ 0–44 45–64 65+ 0–44 45–64 65+ F M T F M T
C15 – 26.7 73.3 2.1 58.5 39.4 1.8 54.1 44.0 15 94 109 1.8 8.5 5.5
C16 3.6 21.0 75.4 2.3 28.7 69.0 2.8 26.0 71.3 167 303 470 19.5 27.3 23.9
C17 16.7 – 83.3 25.0 25.0 50.0 20.0 10.0 70.0 6 4 10 0.7 0.4 0.5
C18 1.0 19.9 79.1 1.4 26.6 72.0 1.3 23.4 75.4 191 207 398 22.3 18.7 20.3
C19 – 11.1 88.9 3.0 21.2 75.8 1.7 16.7 81.7 27 33 60 3.2 3.0 3.1
C20 2.1 21.8 76.1 3.3 31.1 65.6 2.8 27.1 70.2 142 183 325 16.6 16.5 16.5
C21 – 33.3 66.7 – – – – 33.3 66.7 6 – 6 0.7 0.0 0.3
C22 1.1 23.7 75.3 5.2 29.6 65.2 3.4 26.9 69.7 93 115 208 10.9 10.4 10.6
C23 – 15.3 84.7 – 31.8 68.2 – 19.8 80.2 59 22 81 6.9 2.0 4.1
C24 – – 100.0 – 31.3 68.8 – 15.2 84.8 17 16 33 2.0 1.4 1.7
C25 0.9 22.6 76.5 4.1 32.0 63.9 2.5 27.4 70.0 115 122 237 13.4 11.0 12.1
C26 – 5.6 94.4 10.0 10.0 80.0 3.6 7.1 89.3 18 10 28 2.1 0.9 1.4
C18–C21 1.4 20.2 78.4 2.4 28.1 69.5 1.9 24.5 73.6 366 423 789 42.8 38.1 40.2
C23–C24 – 11.8 88.2 – 31.6 68.4 – 18.4 81.6 76 38 114 8.9 3.4 5.8
C15–C26 1.6 20.0 78.4 2.9 31.4 65.7 2.3 26.4 71.2 856 1,109 1,965 43.6 56.4
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TABLE 7
THE NUMBER OF CANCER HOSPITALIZATIONS AND THE AVERAGE LENGTH OF STAY IN HOSPITAL FOR C15–C26 CANCERS,
PERIOD 2001–2006
Females – number of hospital admissions Females – average length of stay
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
C15 – 1 16 19 36 – 25.0 23.3 18.3 20.7
C16 1 36 85 203 325 14.0 12.3 15.4 16.3 15.6
C17 – 1 – 13 14 – 39.0 – 14.7 16.4
C18 – 22 172 355 549 – 14.1 13.3 14.8 14.3
C19 – 2 24 50 76 – 13.5 17.3 15.6 16.1
C20 – 18 165 307 490 – 16.9 13.4 15.7 15.0
C21 – – 1 4 5 – – 8.0 14.8 13.4
C22 – 4 46 104 154 – 14.3 17.1 17.4 17.2
C23 – 1 14 52 67 – 9.0 11.1 19.6 17.7
C24 – 1 2 23 26 – 31.0 34.0 19.7 21.2
C25 – 7 52 108 167 – 13.9 17.3 20.6 19.3
C26 – 2 7 22 31 – 29.5 16.0 17.6 18.0
C15–C26 1 95 584 1,260 1,940 14.0 14.7 14.8 16.4 15.8
Males – number of hospital admissions Males – average length of stay
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
C15 – 3 147 81 231 – 10.7 16.8 21.3 18.3
C16 – 29 213 381 623 – 11.6 14.4 15.6 15.0
C17 – 1 5 5 11 – 77.0 22.8 18.6 25.8
C18 – 29 216 384 629 – 10.8 15.0 13.6 14.0
C19 1 3 38 81 123 12.0 16.3 14.0 16.5 15.7
C20 – 24 274 336 634 – 15.5 16.2 16.5 16.3
C21 – – 1 2 3 – – 12.0 28.5 23.0
C22 – 5 63 109 177 – 24.8 19.6 14.7 16.7
C23 – – 14 14 28 – – 16.8 18.2 17.5
C24 – – 12 15 27 – – 21.3 24.9 23.3
C25 – 8 85 112 205 – 31.6 16.3 18.0 17.8
C26 – 1 2 8 11 – 57.0 3.5 18.8 19.5
C15–C26 1 103 1,070 1,528 2,702 12.0 15.7 15.9 15.9 15.9
Both genders – number of hospital admissions Both genders – average length of stay
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
C15 – 4 163 100 267 – 14.3 17.4 20.7 18.6
C16 1 65 298 584 948 14.0 12.0 14.7 15.9 15.2
C17 – 2 5 18 25 – 58.0 22.8 15.8 20.6
C18 – 51 388 739 1178 – 12.3 14.3 14.2 14.1
C19 1 5 62 131 199 12.0 15.2 15.3 16.2 15.8
C20 – 42 439 643 1124 – 16.1 15.2 16.1 15.8
C21 – – 2 6 8 – – 10.0 19.3 17.0
C22 – 9 109 213 331 – 20.1 18.5 16.0 17.0
C23 – 1 28 66 95 – 9.0 14.0 19.3 17.6
C24 – 1 14 38 53 – 31.0 23.1 21.7 22.3
C25 – 15 137 220 372 – 23.3 16.7 19.2 18.5
C26 – 3 9 30 42 – 38.7 13.2 17.9 18.4
C15–C26 2 198 1,654 2,788 4,642 13.0 15.2 15.5 16.1 15.9
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TABLE 8




Females – number of hospital admissions Females – average length of stay
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
2001 – 17 134 216 367 – 16.8 14.7 16.7 16.0
2002 1 15 89 228 333 14.0 13.4 14.6 15.0 14.8
2003 – 19 90 198 307 – 15.1 16.0 18.0 17.2
2004 – 20 98 219 337 – 13.2 15.0 15.9 15.5
2005 – 10 85 183 278 – 21.2 15.7 16.9 16.7
2006 – 14 88 216 318 – 10.9 12.8 16.2 15.0
C15–C26 1 95 584 1,260 1,940 14.0 14.7 14.8 16.4 15.8
Year of data
collection
Males – number of hospital admissions Males – average length of stay
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
2001 – 23 153 205 381 – 11.8 15.0 16.4 15.6
2002 – 20 211 259 490 – 14.1 14.0 15.2 14.6
2003 – 15 185 279 479 – 21.7 17.6 17.2 17.5
2004 – 13 169 272 454 – 12.1 17.8 14.6 15.7
2005 1 16 160 233 410 12.0 20.1 16.7 18.3 17.7
2006 – 16 192 280 488 – 16.2 14.6 14.4 14.5
C15–C26 1 103 1,070 1,528 2,702 12.0 15.7 15.9 15.9 15.9
Year of data
collection
Both genders – number of hospital admissions Both genders – average length of stay
0–19 20–44 45–64 65+ All ages 0–19 20–44 45–64 65+ All ages
2001 – 40 287 421 748 – 13.9 14.9 16.6 15.8
2002 1 35 300 487 823 14.0 13.8 14.2 15.1 14.7
2003 – 34 275 477 786 – 18.0 17.0 17.5 17.4
2004 – 33 267 491 791 – 12.8 16.7 15.1 15.6
2005 1 26 245 416 688 12.0 20.5 16.3 17.7 17.3
2006 – 30 280 496 806 – 13.7 14.1 15.2 14.7
C15–C26 2 198 1,654 2,788 4,642 13.0 15.2 15.5 16.1 15.9
Fig. 3. The cancer age-standardized mortality rate (ASMR) for cancer group C15–C26 in the period 2001–2006 in the OBC per 100,000
inhabitants using the EU standard population. The downward trendlines in females and males suggest that a strong relationship
exists between ASMR and years, R2=0.672 and R2=0.614, respectively (R2>0.48<0.81).
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Fig. 4. The age-standardized 5-year relative survival rate for cancer group C15–C26 (both genders) in the OBC in the 2001–2005 period.
The downward trendlines in females and males suggest that no relationship exists between 5-years relative survival rates and years,
R2=0.033 and R2=0.195, respectively.
was nearly twice bigger in the 65+ age group than in the
45–64 group (2,788 comparing to 1,654). Also, the length
of stay progressed linearly from the youngest to the old-
est category, precisely from 13 days in the youngest cate-
gory to 16.1 days in the 65+ age group. Considering both
genders, cancer of other and unspecified parts of biliary
tract (C24) lead to the highest average length of stay
(22.3 days). Males with this cancer spent on average 21.2
days in hospital and females 23.3 days. With respect to all
patients together and only male population, the shortest
length of stay on average was found with cancer C18 last-
ing 14.1 and 14 days, respectively. Females with cancer of
anus and anal canal (C21) stayed in hospital on average
longer than females with other cancer sites did, precisely
13.4 days. On average, males stayed in hospital 0.1 days
longer than females did.
The total number of hospitalizations rose from 748 in
2001 to 806 in 2006) (Table 8, Figure 5). The same ten-
dency applies when males are analyzed separately. Fe-
males were characterized by a downward tendency, ex-
cept in the year 2005 when the number of females’
hospitalizations went up substantially. The next year
though experienced the old downward tendency. The
length of stay in hospitals was also featured by a drop in
females, the biggest one occurred in 2002. Males made up
58.2% of all hospitalizations.
Discussion
This is the first paper that elaborates the issue of can-
cer group C15–C26 at a county level in Croatia. The
study conducted in the OBC suggests that the incidence
rate of C15–C26 cancers declined in all age groups com-
paring the first with the second period. It is notable that
the incidence rate was twice higher among males than
among females. The decline in the C15–C26 cancers mor-
tality rate and particularly in the rates of colorectal can-
cer within the OBC population could not be explained by
introduction of the colorectal cancer screening program
since this programme was introduced in 2007.
There were available epidemiological studies which
could show the correlation of the intake of dietary fat and
meat with the risk of colorectal cancer7,23,24.
The changes in incidence rate of cancer group C15–C26
in the OBC may result from changes in detection prac-
tices which appeared after the introduction or increased
use of novel screening, diagnostic or treatment tech-
niques. It seems that the declines in the incidence rates
of rectum cancer (C20) and stomach cancer (C16) and the
increase in incidence rate of colon cancer (C18) in fe-
males in the second period can be explained by omissions
in the coding of diagnoses in hospital facilities and by
manners of its performance and the performance of the
mandatory procedure for filling out cancer application
forms in hospitals. Apart from the aforementioned types
of cancer, all other data suggest a downward trend in the
incidence and mortality rate. During the 1988–2008 peri-
od, the overall gastric cancer incidence and mortality
rate in Croatia decreased steadily25. This study reveals
an increase in the incidence rate in males comparing to
the Croatian average but also a decrease in the mortality
rate among males. The situation with females was oppo-
site. The incidence rate was slightly below the Croatian
average but the mortality rate was twice as high. A quite
similar data relation can be found with colorectal cancer.
The median age at diagnosis of C15–C26 cancer in the
OBC was 67.8 years with a shift of 0.91 years up in the
second period (the first period 67.3 years, the second pe-
riod 68.2 years). The median age at diagnosis of cancer in
females was 69.7 years and in males 66.3 years, which
implies the difference of 2.9 years between genders. The
median age at death from C15–C26 cancers in the OBC
was 70.2 years with a shift of 0.44 years up in the second
period (the first period 70 years, the second one 70.4
years). The median age at death from C15–C26 cancers
in female patients over 65 years of age was 72.5 years
while the respective median age in males was 68.5, im-
plying the difference of 4 years.
The age distribution of cancer patients pursuant to
the gender in the OBC does not differentiate much from
the appertaining age distribution in the USA26,27. Pati-
ents under 45 years of age constituted 3.5% of total can-
cer patients and 2.3% of all deaths from cancer. The dif-
ference between the incidence rate and the mortality
rate in this age was four times bigger than the difference
between the incidence and the mortality rate in total
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Fig. 4. continued.
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Fig. 5. Length of stay in hospital (LOSH) (in days) for cancer group C15–C26 (both genders, selected sites) in the OBC in the 2001–2006
period (NOA – number of hospital admissions). There is no relationship between length of stay in hospital and years (females and
males), but strong and very strong relationship between length of stay in hospital and age for females (R2=0.770) and males
(R2=0.815), respectively.
cancer (C00–D48) in the OBC. The difference in the age
distribution at death was even more evident (2.3% to
0.2%)3. As many as 72.8% of female cancer patients and
60.6% of male cancer patients was over 65 years of age at
diagnosis with cancer. On average, females got diagnosis
from C15–C26 cancers 12.2 years later than males did. A
similar difference was determined with the respective
mortality (12.7 years). There has not been any study in
the OBC, which would be aimed at finding reason for this
disproportion.
Cancer survival rates represent a direct consequence
of different cancer control activities such as early detec-
tion, cancer care delivery and access or appropriate treat-
ment. Very few studies focusing on cancer survival have
been conducted in Croatia so far and most estimates are
outdated in terms of comparison28. The survival from
C15–C26 cancers strongly depends on age29. The overall
5-year relative survival rate from these cancers in the
OBC is still significantly lower than that in European
countries, particularly concerning oesophagus cancer
(C15) and colorectal cancer C18–C2130. In the OBC, the
survival rate from C15–C26 cancers was in all ages
slightly higher in females than in males, which is oppo-
site from the situation in the USA9. In the Primorsko-
-Goranska County, there are data on estimated 5-year
survival rate (observed survival) of patient with colorec-
tal cancer (from 1980 to 1999) accompanied with differ-
ent cancer stage and various medical treatments31,32. Un-
fortunately, these data cannot be compared with the data
on observed survival from colorectal cancer in the OBC
(unpublished data on this survival, used as a ground for
calculation of the 5-year relative survival rate, suggest
the total overall observed survival rate of 23.3%, males
22.8%, females 24%) due to a different methodology of
data processing).
The reference period was characterized by a rise in
the number of hospitalizations of males (all age catego-
ries) diagnosed from cancers of digestive organs while
the appertaining figure went down in females. The aver-
age length of stay in hospital changed (increases signifi-
cantly) with the age of patients (Figure 5). The largest
number of hospitalization was a result of colorectal can-
cer which was followed by the stomach cancer. Unfortu-
nately, the data on cancer patients does not include (al-
though they ought to) information on the performed
treatment during hospital care such as the type of surgi-
cal treatment, chemotherapy, radiation etc. Therefore,
the hospitalizations and the length of stay in hospital can
only be commented generally and not individually on a
single patient basis. What cannot be derived from these
data is what exercise direct influence on the length of
stay in hospital, its connection with the outcome of the
treatment, dynamics of the change of treatment costs
and the answer to the question if one should strive for a
shorter length of stay in hospital or not33,34. The differ-
ence in the length of stay in hospital between the youn-
gest and oldest age category amounted to 2.9 days in the
OBC (13 and 15.9 days, respectively, Table 8) and it re-
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sembled the respective difference in the USA, bearing in
mind the fact that the length of stay in hospital due to
this type of cancer is in the USA 3–4 shorter than in the
OBC35.
Incidence and mortality rates of the cancers of the di-
gestive system in the OBC do not differ significantly
from the data for the Croatia as a whole, but are well
above the EU average. On the other hand, the survival
rate is much lower than the EU average which is a direct
indicator of the health service functioning and requires
urgent and quality response. At the level of Croatia as a
whole, including the OBC there are preventive programs
that focus on education of citizens about measures and
actions that could be taken in the prevention and early
detection of cancers of the digestive system.
Limitations
Patients who were treated outside the hospital in the
OBC are not registered in IPHO. Despite the efforts to
get this information (they exist at the national level) in
their original form, the authors were unable to obtain
that data for unknown reasons. Therefore, the data of
cancer in the OBC may differ from data of cancer for the
OBC at the state level.
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RAK PROBAVNIH ORGANA (C15–C26) U OSJE^KO-BARANJSKOJ @UPANIJI, HRVATSKA
S A @ E T A K
Zavod za javno zdravstvo Osje~ko-baranjske `upanije je u suradnji s razli~itim tijelima dr`avne uprave i Maticom
umrlih na razini `upanije prikupljao i obradio podatke o osobama oboljelih od raka za podru~je Osje~ko-baranjske `upa-
nije (OBC) koriste}i se obvezatnim bolni~kim prijavama oboljelih. Za {ifriranje raka probavnog sustava kori{tena je
Me|unarodna klasifikacija bolesti, 10-ta revizija, C15–C26. Cilj rada je prikazati veli~inu problema i optere}enost
zdravstvenog sustava karcinomima probavnog sustava C15–C26 u OBC u razdoblju od 2001–2006. ^lanak obra|uje
incidenciju i smrtnost, dobnu raspodjelu, prosje~nu dob oboljelih i umrlih, 5-godi{nje relativno pre`ivljavanje te broj i
du`inu hospitalizacija u bolnicama OBC. Koriste}i EU standardnu populaciju prosje~na stopa incidencije i smrtnosti u
promatranom razdoblju je 101,1 odnosno 80/100.000. Prosje~na stope incidencije u promatranom {estogodi{njem raz-
doblju za grupu raka C15–C26 (101,1 i 80/100.000, EU standardne populacije) pada u drugom trogodi{njem razdoblju
(prvo razdoblje 2001–2003, 104,9/100.000 i drugo razdoblje 2004–2006, 97,2/100.000). Stopa smrtnosti tako|er pada od
83.4 u I razdoblju na 76,6/100.000 u II razdoblju. U trenutku postavljanja dijagnoze raka prosje~na dob je bila 67,8
godina s pomakom od 0,91 godina u stariju dob u drugom razdoblju (67,3 na 68,2 godine). Prosje~na dob prilikom
dijagnoze raka je 69,7 godina u `ena i 66.3 godine u mu{karaca s razlikom do 3,4 godina za `ene. Relativno 5-godi{nje
pre`ivljavanje za sve dobi i oba spola je 23,6%, neznatno vi{e u `ena (24,3%) nego u mu{karca (23,1%). U promatranom
razdoblju porastao je broj hospitalizacija uzrokovanih karcinomima probavnog sustava u mu{karaca vidljiv u svim dob-
nim skupinama, dok se smanjuje broj hospitalizacija u `ena. Prosje~na duljina le`anja se s godinama ne mijenja. Sijela
raka C15–C26 su naju~estalija skupina raka u oba spola. 5-godi{nje pre`ivljavanje kao jedan od pokazatelja kvalitete
rada zdravstvene slu`be ostavlja prostor za bitno unapre|enje kako bi se u {to kra}em razdoblju pribli`io EU prosjeku.
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